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Abnormalities of the p53 tumor-suppressor gene are found in a significant proportion of astrocytic brain tumours. We studied
tumour specimens from 74 patients evaluated over 20 years at the Massachusetts General Hospital, where clinical outcome could be
determined and sufficient pathologic material was available for immunostaining. p53 expression studies employed an affinity-purified
p53 monoclonal antibody, whose specificity was verified in absorption studies and, in a minority of cases, a second antibody
recognising a different epitope of p53. Significant overexpression of p53 protein was found in 48% of the 74 tumours included in this
series and high levels of expression were associated with higher mortality from astrocytic tumours (Po0.001, log rank). Multivariate
analyses revealed that immunohistochemically detected p53 was an independent marker of shortened progression-free and overall
actuarial survival in patients with astrocytic tumours, suggesting that increased expression of p53 plays an important role in the
pathobiology of these tumours. In a subset of 36 cases, coding regions of the p53 gene were completely sequenced via SSCP and
direct DNA sequencing, revealing that overexpression of p53 protein is not always associated with point mutations in conserved
exons of the p53 gene. Finally, we confirmed p53 protein expression in early-passage human glioma cell lines of known p53
mutational status and immunostaining scores. Although grade continues to be the strongest prognostic variable, the use of p53
staining as a prognostic indicator, in contrast to mutational DNA analyses, may be a useful adjunct in identifying patients at higher risk
of treatment failure.
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Alterations of the p53 tumour suppressor gene may be the most
frequent abnormalities identified in human cancer. Early studies
suggested that p53 abnormalities contribute to the development of
malignant transformation in astrocytic brain tumours (Frankel
et al, 1992; Sidransky et al, 1992). Loss of heterozygosity on human
chromosome 17p, 53 point mutations, and altered p53 expression
were reported in astrocytomas (Scheffner et al, 1990; Werness et al,
1990; Fujimaki et al, 1991; Lowe and Ruley, 1993; Chozick et al,
1994a; Iuzzolino et al, 1994; Slebos et al, 1994; Morita et al, 1996;
Sarkar et al, 2002). Our goal is to assess the significance of
potential alterations in p53 protein expression, and its inter-
relationship with more traditional prognostic factors in astro-
cytoma tumour progression, in rigorous fashion.
Studies evaluating the prognostic significance of p53 abnorm-
alities in human tumours were hampered initially by technical
limitations imposed on detailed DNA mutational analyses using
archival pathologic specimens. Monoclonal and polyclonal anti-
bodies for p53 that reliably detect p53 protein in routine formalin-
fixed histologic material have been developed. This approach
revealed abnormalities, not only of mutant p53 protein, but also of
apparently wild-type p53 protein (Barnes et al, 1992). Although
most previous studies emphasised the importance of immunos-
taining as a screening procedure to identify patients with mutant
p53 DNA alleles, immunostaining can also reveal an expanded
spectrum of disease due to overexpression of nonmutant or wild-
type p53 (Kurtkaya-Yapicier et al, 2002). In this report, we
demonstrate the importance of overall p53 overexpression as an
independent determinant of patient clinical core in astrocytic
tumours. An expanded role for the importance of quantitative
abnormalities in overall p53 expression is suggested by our finding
that overexpression of p53 protein in astrocytic tumours may not
be accompanied by detectable point mutations in coding exons of
the p53 gene. The correlation we report between clinical
progression-free survival and overexpression of p53, and its
relationship to other clinical factors of importance in astrocytoma
tumour progression, suggests that quantitative increases in
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yexpression of overall p53 protein are biologically significant in the
neoplastic process of astrocytic tumours. Despite these intriguing
statistical correlations, it should be noted that grade per se was the
strongest prognostic factor, and remains the ‘gold standard’ in
determining survival from astrocytic tumours.
METHODS
Patients
We examined a population of 74 patients with astrocytic tumours
among patients treated for brain tumours at the Massachusetts
General Hospital (MGH) between 1970 and 1990, for whom
archival tissue were available and clinical outcome could be
determined from medical records. The population characteristics
of the cases were similar to those of the overall patient population
evaluated at the MGH during the two decade period, as determined
from MGH Tumor Registry data. In particular, the populations
selected for study were indistinguishable with respect to overall
tumour grade, patient age, gender, and the use of postoperative
chemotherapy or radiation therapy. Actuarial overall survival was
determined from the medical records as the time from pathologic
confirmation of the surgical specimen to the time of death of the
patient, with censoring occurring for intercurrent death from
nontumour-related causes, and patients lost to follow-up. Progres-
sion-free survival was similarly determined as the time from
pathologic confirmation of the surgical specimen, prior to therapy,
to the first time of disease progression, as evidenced by a persistent
20-point decrease in Karnofsky functional status and available
clinical and/or radiographic data. Survival end points were
compared to standard prognostic factors that included patient
age, sex, tumour grade, tumour size, Karnofsky score, and
therapeutic interventions (extent of primary surgical debulking,
radiation treatment, chemotherapy, and reoperation). All speci-
mens examined were from the initial surgical specimen, prior to
the administration of either radiation or chemotherapy. The
tumour block deemed most representative of the overall surgical
specimen was used for subsequent immunohistochemical analyses.
In a subset of cases, additional blocks containing tumour tissue
were also employed in immunohistochemical analyses in order to
address potential heterogeneity in protein expression among the
different paraffin blocks. Tumour grade was scored by the
neuropathology staff at MGH prior to this study and those grades
were confirmed by one neuropathologist at MGH MGH who
rescored the tumour grades without knowledge of the p53 staining
scores for the tissues (E Tessa Hedley-Whyte). Pathologic scoring
was classified performed according to the World Health Organiza-
tion Grading System (Radner et al, 2002). There were no pilocytic
tumours in our clinicopathologic series. Therefore, stratification
by pathologic criteria was grouped by ‘astrocytoma’ (WHO, grade
II) vs anaplastic (malignant) astrocytoma and glioblastoma (WHO
grades III,IV). Daumas-Duport criteria, as grades 1–4. Since the
Daumas-Duport scale is only defined for adult supratentorial
astrocytoma, 13 cases of astrocytoma, otherwise felt to be low
grade by traditional histopathologic criteria, were also included in
this study (Daumas-Duport et al, 1988). Mixed oligoastrocytic
tumours were not included in this study because these types are
not of pure astrocytic lineage.
Immunohistochemistry
Immunohistochemical studies were performed on archival para-
ffin-embedded material from all 74 cases. In all, 10–15 5mm
sections were obtained from each block. Normal horse serum
(DAKO) was used to block slides for approximately 20min prior to
the application of antibody. Antibody PAb1801 (Crawford; UK;
Oncogene Science, Uniondale, New York, USA) was used at
dilutions of 1:125. Antibody incubations were conducted for 1h at
room temperature or overnight at 41C. A biotinylated secondary
antibody (Vector) recognising the primary antibody was applied
for 20min prior to the application of a streptavidin–peroxidase
complex (Vector) for 30min. Diaminobenzidine (Sigma) in
phosphate-buffered saline was used as substrate for development
of the peroxidase reaction. Owing to the preferences of the
pathologists characterising the staining, slides were counterstained
with haematoxylin. The brown immunoperoxidase reaction
product was then easily discernable from the counterstain under
regular illumination. In order to standardise immunostaining
runs, each independent observer categorised the depth of staining
as dark, medium, or light, and the quality of the staining as
granular or diffuse. All scoring of cells was conducted at  40
magnification. Oil immersion was rarely required for differentia-
tion of immunoreactivity from nonspecific or counterstaining
effects. Using these procedures, negative control slides containing
paraffin-embedded Saos-2 cells (deleted in both p53 alleles)
showed no staining over background, as verified by three
independent pathologists. In addition, 20 individual autopsy cases
containing normal cortex, midbrain, and brainstem showed no
detectable immunostaining over background.
To ensure reproducibility, each case was stained at least twice.
In a subset of cases, at least two blocks obtained from different
regions of the respective tumours were evaluated in order to
address issues of heterogeneity in protein expression. An
additional round of staining occurred in cases with immunostain-
ing scores differing by 1 score category (p25% of cells). Scoring of
the immunostaining was performed independently by three
observers. All of the cases were examined by all three observers
in order to derive concordance scores for standardisation of the
scoring categories. We included immunostaining categories as
follows: (0) no detectable protein over background; (1) p10% of
cells staining; (2) 410–p25% of the cells staining; (3) 425–
p50% of cells staining; (4) 450–p75% of cells staining; and (5)
475% of cells staining. In an attempt to address issues regarding
nonspecific staining effects and batch-to-batch variability, note
was taken of degrees of immunoreactivity by categorisation of the
depth of the staining as dark, medium, or light, and the quality of
the staining as granular or diffuse.
In order to assess p53 immunoreactivity using an antibody
recognising a different epitope of p53, a second antibody was
employed, D0-1 (Oncogene Science, Manhasset, NY, USA) 31
cases. As opposed to PAb 1801, an IgG1 monoclonal recognising
residues 46–55 of human p53, antibody DO-1 is an IgG2a
monoclonal recognising residues 21–25 of human p53. Following
a preliminary series of experiments on control material, the
optimal dilution for the batch of antibody used was determined as
1:50. The remainder of the immunohistochemistry procedure was
as described above. Based on the spectrum of percent immuno-
positive cells, staining categories were determined as follows: (0)
No immunoreactivity; (1) o1% of cells immunoreactive; (2)41–
p10% immunoreactive; (3) 410–p30% immunoreactive, (4)
430% immunoreactive.
Absorption of p53 antibodies
All cases receiving staining scores greater than 0 on the percentage
scale were also stained with preabsorbed PAb1801 antibody.
Human recombinant mutant p53 (ARG 273 HIS) was expressed in
Escherichia Coli strain BL2 (DE3)LysS transfected with human
mutant p53 cDNA cloned into the T7 expression plasmid pT7-7
(from C Midgley and D Lane, University of Dundee, UK).
Recombinant p53 was purified by immunoaffinity chromato-
graphy using antibody PAb240 and then coupled to CNBr-acti-
vated Sepharose 4B. A solution containing 100mg of PAb1801 IgG
and 0.2% gelatin was applied to the p53 protein-affinity column.
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flow was stopped. After 5min, flow was resumed and fractions
were collected. Fractions spanning the peak of total protein eluting
from the column (representing the gelatin present in the starting
material) were pooled.
The titre of the absorbed PAb1801 was determined by ELISA
using 96-well microtitre plates coated with purified human
recombinant p53. Absorbed and lot-matched unabsorbed anti-
bodies were diluted using six serial 10-fold dilutions from 1:10
2 to
1:10
7 in dilution buffer (PBS containing 0.1% BSA). A volume of
100ml of each diluted antibody preparation was added to duplicate
ELISA wells and incubated for 4h at 371C. Wells were washed and
further incubated for 2h at 371C using 100ml of peroxidase-
conjugated goat anti-mouse IgG (Oncogene Science, Inc.) diluted
to 2mgml
 1 in dilution buffer. After washing, 100ml of peroxidase
substrate was added to each well and the absorbance was
determined at 405nm (Bio-Tek Instruments Microplate reader,
Model EL320). Antibody titre was defined as the reciprocal of
dilutions rendering absorbances at 405nm, 4 times background
(background¼0.024AU). The residual PAb1801 activity, com-
pared with the unabsorbed antibody, was found to be 0.05% for the
same antibody lot used for immunohistochemistry.
Evaluation of cytokeratin cross-reactivity
Cross-reactivity with keratin was reported in previous p53
immunostaining studies of astrocytomas (Sembritzki et al, 2002).
Since cytokeratin immunoreactivity is recognised in gliomas and
such immunoreactivity could confound results, all cases receiving
p53 staining scores greater than 1 were also stained with a mixture
of anticytokeratin antibodies consisting of AE1 and Cam 5.1
(Vector Laboratories). For positive tissue controls, a paraffin-
embedded squamous cell carcinoma and a pituitary adenoma were
compared. Negative control tissue included a malignant fibrous
histiocytoma and a desmoid tumour. Approximately 10ml of each
of the primary antibodies were employed at dilutions of 1:1000.
The remainder of the immunohistochemistry procedure was
performed as described above.
p53 mutation analysis
In a subset of 36 tumours included in the study, DNA and RNA
was harvested at the time of initial surgery. DNA extracted from
tumour tissue, using standard procedures (phenol/chloroform and
ethanol precipitation) was dissolved in 10mM Tris, pH 7.5 and
1m M EDTA and stored at 41C. To screen for the presence of point
mutations with the single-strand conformational polymorphism
technique (SSCP), nine sets of primers were generated to amplify
DNA fragments encompassing exon 2, and exons 4–11 of the p53
gene. The primer sequences and fragment lengths are described by
Mashuyama (Mashuyama et al, 1991). The polymerase chain
reaction (PCR) was performed using 100–500ng of template DNA
in 50mM Tris-HCl, pH 8.6 with 1.5mM MgCl2, 0.200mM of each
dNTP, 250ng of each primer, 1ml of
32P-dCTP (3000Cimmol
 1)
diluted 1:10 and 2.5U Taq polymerase (AmpliTaq, Cetus) in a
50ml total reaction volume. Reaction conditions for the Perkin-
Elmer 480 Thermocycler were: 941C (45s), 551C (45s), and 721C
(45s) for 35 cycles. The reaction was initiated with a 6min ‘hot
start’ incubation at 941C, and was completed with a 7min
extension at 721C, followed by 3min at 921C. A volume of 5mlo f
the PCR product were added to 5ml loading buffer (95%
formamide, 20mM EDTA, 0.05% bromophenol blue, and 0.05%
xylene cyanol). The samples were denatured for 5min at 851C and
loaded immediately into a 6% polyacrylamide-TBE nondenaturing
gel containing 1–10% glycerol. Electrophoresis and autoradiogra-
phy followed standard procedures. DNA samples determined to be
abnormal by multiple SSCP analyses were amplified with the SSCP
primers encompassing the abnormal region. Fragments were
directly subcloned into PCR vector using the TA cloning TM
system kit (In Vitrogen), and sequenced by the Sanger dideoxy-
nucleotide method using a Sequenase 2.0 kit (US Biochemical). For
each sample in which a base-pair alteration was identified,
duplicate PCR reactions were performed to rule out the possibility
of PCR-generated artefact.
Statistical analyses
The following prognostic factors were derived from patient
medical records and entered as independent variables into clinical
databases: age, sex, initial tumour size, extent of surgical resection,
radiation therapy dose and technique, chemotherapy, tumour
grade, percentage of cells demonstrating p53 immunoreactivity,
and Karnofsky performance status initial, postoperative preradia-
tion or chemotherapy, following radiation/chemotherapy, and at
time of last follow-up. Times to last clinical follow-up and disease-
specific death were measured from the date of pathologic
confirmation of the surgical specimen. In cases with multiple
resections, only the tissue from the initial surgical resection, prior
to the administration of radiation therapy or chemotherapy, was
used for immunohistochemistry. The Kaplan – Meier Product-
Limit method was used to estimate survival probabilities with
statistical inferences on actuarial curves made using the log-rank
test (Kaplan and Meier, 1958). Cox’s proportional hazards
regression was used to control for the simultaneous effect of
outcome-related covariates (Cox, 1993). Martingale residual plots
were used to assess model fit (Therneau et al, 1990). For all of our
models, the ratio of hazards remained constant and the median
follow-up time among censored patients was comparable between
groups. Logistic regression and Fisher’s exact two-tail test were
used to examine the relationship between: p53 (low:o25% of the
cells demonstrating immunoreactivity vs high:425% of the cells
positive) and the prognostic factors grade (1–2 vs 3–4), Karnofsky
score (470 vs p70), age (p55 vs 455), size (p4 vs 44cm), sex
(female vs male), radiation dose (X6000 vs o6000cGy), and
chemotherapy (yes vs no). Since cutoff values were determined
retrospectively, P-values were adjusted using the Bonferroni
method (Bowker and Lieberman, 1972). Sensitivity and specificity
were calculated with respect to a classification cutoff of P¼0.50.
For survival analyses involving the subset of patients stained
using Antibody DO-1, statistical analyses were conducted in
identical manner. Since the greatest amount of immunoreactivity
observed using this antibody approximated 50% of the cells
staining positive, the p53 immunostaining categories differed as
follows: p53 (low: o10% of the cells with immunoreactivity vs
high: 410% of the cells staining positive).
RESULTS
p53 staining and patient outcome
Expression of p53 protein was compared to clinical outcome on
both univariate and multivariate statistical analyses in order to
determine whether the accumulation of p53 protein in tumour cells
was important in the biological behaviour of astrocytomas. The
clinical characteristics of the patient population are depicted in
Figure 1. Overall progression-free survival for the population of 74
patients is noted in Figure 1A. Interestingly, a low immunostaining
score was a significant predictor of good clinical outcome
(Figure 1B, Po0.0001). Similarly, increased tumour grade and
patient age greater than 55 years correlated with poor clinical
outcome (Figure 1C, D; Po0.001). This suggests that expression of
p53 is a significant event in the natural history of astrocytic
tumors.
Tumour grade, p53 immunostaining score, and patient age
were the most significant prognostic factors using univariate
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tumour size, extent of surgical resection, Karnofsky index,
radiation dose, use of chemotherapy, or patient sex did not
predict patient outcome as well as p53 staining. The correlation of
p53 staining scores with each prognostic factor is given in Table 2.
Significant correlations were found when p53 expression was
compared to tumour grade, Karnofsky score, patient age or
tumour size. We examined such correlations with survival in detail
using multivariate analyses to determine whether p53 expression
was independent of other factors that predict clinical outcome in
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Event - free survival
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AB
C D
Figure 1 (A) Progression-free survival of the entire group of 74 patients. (B) Progression-free survival by grade. Grade I and II vs Grade III and IV. (C)
Progression-free survival by age greater than or less than 55 years. (D) Progression-free survival by p53 expression. p53 high (at least 25–50% of the cells
staining positive) vs P53 low (less than 25% of the cells staining positive).
Table 1 Relationship between p53 immunostaining and other prognostic factors (N¼74)
Factor
Number of
patients p53
low
Wald p53
high
Sensitivity
v
2
Odds ratio
(95% CI; P)
Specificity
(P¼0.50)
Fisher’s
(P¼0.50)
Exact
(two-tail)
Grade 1, 2 25 4 18.8 15.4 (4.5–53.0; o0.01) 65.8% 88.9% Pp0.01
3, 4 13 32
Karnofsky X70 16 5 6.7 4.5 (1.4–14.1; 0.010) 42.1% 86.1% P¼0.009
p70 22 31
Age p55 32 21 5.7 3.8 (1.3–11.4; 0.020) 84.2% 41.7% P¼0.020
455 6 15
Size p4 14 5 4.8 3.6 (1.1–11.4; 0.029) 36.8% 86.1% P¼0.033
442 4 3 1
Sex Female 17 12 1.0 1.6 (0.63–4.1; 0.317) 44.7% 66.7% P¼0.349
Male 21 24
Radiation 46000 6 3 0.9 2.1 (0.48–9.0; 0.334) 15.8% 0.0% P¼0.481
p6000 32 33
Chemotherapy Yes 27 23 0.4 1.4 (0.52–3.7; 0.511) 71.1% 36.1% P¼0.511
No 11 13
Resection Biopsy gross residual 8 2 3.3 4.5 (0.89–23.03; 0.068) 21.1% 94.4% P¼0.087
Microscopic residual, total
resection
30 34
Prognostic factors for the overall population as stratified by p53 expression low (score 0–2) vs high (score 3–5): sex, Karnofsky performance status score, grade, extent of
surgical resection, and the use of radiation therapy or chemotherapy.
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staining score was an independent variable in predicting clinical
outcome (Table 3). In a proportional hazards model, p53 scores
contributed additional predictive value for patient outcome when
comparisons included tumour grade, patient age, tumour size, or
Karnofsky score. Thus, the p53 protein immunoreactivity score did
not merely reflect any other prognostic factor.
Immunostaining
The reliability of our immunohistochemical screening for p53,
using the 1801 monoclonal antibody, was tested during this study.
First, a cell line with both alleles of the p53 gene deleted (Saos-2)
was included in all staining procedures to control for antibody
dilutions. Second, none of the tumours with high immunostaining
demonstrated cytokeratin immunoreactivity. Finally, we ensured
that positively staining specimens were specifically expressing p53
by comparison to staining of the identical tumour specimens with
an antibody that had been preabsorbed with recombinant p53; in
all cases, the absorbed antibodies stained at background levels
(Figure 2). A striking finding in our study was the heterogeneity in
protein expression found, not only among different tumours, but
among different cells in histopathologic sections from the same
specimen. In order to minimise heterogeneity in protein expres-
sion as a factor confounding the determination of the overall
percentage of cells staining positive, each case was stained at least
twice. In 62/70 cases, the staining score categories differed by no
more than one score category. In five out of the eight remaining
cases, a third or fourth staining run was required to obtain
consistent pathologic findings. In the three remaining cases, the
lowest of the staining scores was used for entry into clinical
multivariate analyses. In addition, overall staining score
concordance was reproducible in 66 out of 74 cases (89%).
Thus, despite heterogeneity in expression, the staining score
categories were quite reproducible among the three independent
observers.
In order to assess the generality of our results with Ab 1801,
another antibody, D0-1, was used in a subset of 31 cases judged to
have sufficient remaining archival clinical material. The greatest
amount of immunoreactivity observed using this antibody
approximated 50% of the cells staining positive. Thus, the
immunostaining categories reflect high p53 immunostaining as
410% of the cells staining positive. Using this criterion,
overexpression of p53 was associated with decreased progres-
sion-free survival times on univariate analyses (Po0.04). Owing to
the smaller sample size, however, statistical significance was not
achieved on multivariate survival analyses.
p53 staining and mutational analysis
Previous studies concentrated on the employment of immunos-
taining as a screening study to identify tumours containing
p53 DNA mutations based on the premise that p53 mutations
led to overexpression of p53 protein. In a subset of 36 patients
we included in the immunostaining series, frozen tissue was
available for molecular analyses. Additional molecular
analyses were performed to assess the relationship between
p53 mutation and p53 protein expression. The p53 coding
sequences for exons 2–11 in DNA extracted from the primary
tumours was completely sequenced in all of these cases. We found
mutations in 13 out of these 36 tumours. All of these mutations
were found in exons 4–8. Interestingly, one sample revealed a
10bp deletion in exon 4, resulting in a stop codon. Although the
sample corresponded to a patient with glioblastoma or Daumas-
Duport grade 4/4 astrocytoma, the immunostaining data revealed
o25% of cells positive, and an unusually long progression-free
survival time of 20 months. An additional six cases overexpressing
p53 protein showed no p53 DNA mutations. Thus, the data
indicate that p53 overexpression can occur in the absence of
mutations in coding sequences of the p53 gene, and suggests that
Table 2 Kaplan – Meier statistics for the individual prognostic factors
Variable Wald v
2
Log rank
P
Survival
ratio
Grade [(1,2) vs (3,4)] 31.2 0.0001 15.7
P53 (low vs high) 25.4 0.0001 5.2
Age (p55 vs 455 years) 22.6 0.0001 4.7
Size (p4 vs 44cm) 8.9 0.0014 3.7
Karnofsky (o70 vs X70) 7.4 0.0047 2.8
Resection (biopsy, gross residual vs
microscopic residual, total resection)
4.0 0.0035 3.3
Chemotherapy (no vs yes) 0.1 0.8039 1.1
Sex (male vs female) 0.0 0.9757 1.0
Progression-free survival (Kaplan – Meier model) (N¼74, # events¼46, %
censored¼37.84).
Table 3 Multivariate analyses for the individual prognostic factors listed.
p53 expression status rendered additional prognostic information when
age and grade were controlled for in multivariate analyses
Variable Wald v
2 P-value
Survival
ratio
Age (o55 vs 455 years) 4.0 0.0456 2.0
Grade (1–2 vs 3–4) 16.3 0.0001 8.9
p53 (low vs high) 4.1 0.0426 1.9
p53 (low vs high) 14.4 0.0001 3.7
Age (p55 vs 455 years) 8.7 0.0032 2.7
Size (p4 vs 44cm) 2.6 0.1066 2.1
p53 (low vs high) 15.3 0.0001 4.0
Age (p55 vs 455 years) 11.7 0.0006 3.1
Resection (biopsy, gross residual vs
microscopic residual, total resection)
0.2 0.6480 1.3
Progression-free survival (proportional-hazards model) (N¼74, # events¼46, %
censored¼37.84).
Figure 2 Shown is a grade 4/4 astrocytoma revealing a nuclear pattern
of staining; however, following absorption of PAb1801, the nuclear staining
decreases to background levels, thus demonstrating the specificity of the
immunohistochemistry reaction.
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is consistent with a statistically significant increase in progression-
free survival times (Figure 3).
Interestingly, the heterogeneity noted on protein expression
studies was similarly noted on the DNA mutational level.
DISCUSSION
It is well-recognised that alterations in p53 protein expression
cause abnormalities in cell cycle regulation (Agami and Bernards,
2000). Normal p53 protein can block cells in the late G1 phase of
the cycle, just prior to DNA synthesis, while mutant forms of this
protein fail to arrest cell cycle progression and can promote
cellular proliferation. Many studies of p53 expression stress the
importance of the prolonged half-life of mutant p53 that allows
protein accumulation in neoplastic tissue (Gannon et al, 1990).
Several studies documented the importance of either wild-type or
mutant p53 alleles in leading to increased expression of p53
protein increased expression of both wild-type and mutant p53
protein. Furthermore, the overexpression of wild-type p53 protein
in human tumour specimens, as well as histologically benign
lesions without p53 mutations, suggests a role for overexpression
of p53 protein through overlapping mechanisms, idependent of
actual p53 mutations (Barnes et al, 1992; Chozick et al, 1994b;
Kurtkaya-Yapicier et al, 2002).
Our main goal was to determine, in rigorous fashion, whether
abnormalities in p53 expression might play a role in the biologic
outcome of patients with astrocytic brain tumours. We found that
positive p53 staining was a significant predictor of poor clinical
outcome in astrocytic tumours. As a predictor of outcome, p53
staining contributed to prognosis as an independent variable when
compared with age, sex, tumour grade, Karnofsky score, or
therapeutic approach. Although grade was the most statistically
significant variable examined with respect to survival in astro-
cytomas, p53 expression was an independent predictor of patient
survival. It should be noted that we were conservative in our
statistical analyses of grade as a binary grouping (grades I–II vs
grades III–IV). Indeed, in analyses where we examined grade as a
continuous variable (I–IV), a higher level of statistical significance
was achieved (data not shown). In like fashion, if we examine p53
protein expression as a continuous variable (all individual
immunostaining score categories) rather than as a binary variable
(p25 vs 425%), higher levels of statistical significance are once
again achieved (data not shown). Even in this conservative setting,
however, the levels of statistical significance achieved, independent
of both grade and age, suggest that overexpression of p53 protein
is important in the natural history of these aggressive tumours.
Finally, p53 expression was measured with an antibody
recognising a different epitope of p53. Again, overexpression of
p53 protein was associated with decreased progression-free
survival times on univariate analyses. There was high concordance
among cases overexpressing p53 with both antibodies. In all 9 out
of 10 cases overexpressing p53 using Ab 1801, also overexpressed
with Ab DO-1. Similarly, 14 of 16 cases demonstrating relatively
low immunoreactivity using Ab DO-1 also showed low immunos-
taining scores using Ab 1801. Thus, 23 out of 26 cases revealed
concordant immunostaining scores using either antibody. The fact
that immunostaining categories with DO-1 differed from those
established for Ab 1801, is not surprising given the lot and batch to
batch variability of commercial preparations and the different
antigen recognition site of the antibody. The technical complexity
of archival studies emphasising various methodologic approaches
to the interpretation of immunoreactivity was previously ad-
dressed (Fisher et al, 1994). Clearly, the absolute magnitude of
standards for immunoreactivity will vary among investigators and
clinical laboratories, though the relative degrees of immunostain-
ing should be comparable.
Wild type
Mutant
B3
B4
B5
B12
B13
B14
B15
B16
B17
B19
B22
B117
A
A
G
G
C
CC
T
T T
A
B
Figure 3 (A) A SSCP analysis of exon 8 of the p53 gene run on 12%
polyacrylamide gel with 1% glycerol at 10W for 16h. Note band shift in
lane marked B 16 (indicating a p53 alteration). The shift is a result of
conformational changes induced by the point mutation identified in the
sequencing gel in (B). (B) DNA sequence analysis of exon 8 for sample B
16 indicating base pair substitution at codon 273 changing an arginine
residue to histidine. Nucleotide base pairs: A¼adenine; G¼guanine;
C¼cytosine; T¼thymine.
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we were primarily interested in assessing the interval of time
during which the patient was free from significant neurologic
deterioration due to tumour-related causes. This is particularly
relevant with these rather heterogeneous tumour types, consisting
of low-grade astrocytomas of rather long natural histories, and
higher grade tumours with relatively short clinical progression-free
intervals. While the differentiation of recurrent tumour vs
radiation-induced morbidity can be complex, especially in the
era preceding magnetic resonance imaging or positron emission
tomography, a significant proportion of our patients underwent
reoperation and/or necropsy within 1 month of their last clinical
trial. Our identification of astrocytoma cases with high immuno-
staining scores, in the absence of mutations in coding sequences of
the p53 gene, suggests that p53 may act through downstream
mechanisms that are distinct from purely tumour-suppressive
functions in its native form, or as a dominant-negative regulator in
mutant or oncogenic forms. Normal cellular proteins that bind to
p53 in a manner similar to viral oncoproteins were identified and
found to be potential oncogenes (Scheffner et al, 1990; Bargonetti
et al, 1991; Debbas and White, 1993; Nees et al, 2001; Cobbs et al,
2003; Dai et al, 2003; Calogero et al, 2004). Proteins implicated in
cell cycle regulation may serve as downstream effectors of p53
function (Dulic et al, 1994; Agarwal et al, 1995; de Toledo et al,
1998; Skomedal et al, 1999; Ghimenti et al, 2003). The 1801
monoclonal antibody employed in our study detects a mammalian-
specific epitope of both mutant and wild-type p53 protein.
Although, based on the longer half-life of mutant p53, one might
initially infer that most of the accumulation is due to over-
expression of mutations in p53, overexpression of wild-type p53
would also be detected by this antibody (Gannon et al, 1990). Since
the 1801 monoclonal antibody recognises total p53 expression, as
was previously reported on archival paraffin-embedded prepara-
tions, we specifically chose to employ it in our studies. Although
the so-called mutant-specific p53 antibodies exist, there is no
antibody, to our knowledge, that recognises the entire mutational
spectrum of p53 protein conformational changes. The discrimina-
tion of mutant vs wild-type p53 protein with the antibodies
reported to date remains controversial (Fisher et al, 1994). More
importantly, although prior reports emphasised the role of p53
mutation in leading to overexpression of p53 protein, the role of
wild-type p53 overexpression in glial tumour progression has
received considerably less attention (Rubio et al, 1993; Pollack et al,
2001, 2002). Several reports suggest that normal p53 protein may
accumulate in tumours without DNA mutations, although, to our
knowledge, no relationship among factors known to be of
prognostic importance in astrocytic tumours has yet been
described to establish clinical significance across the histologic
spectrum of pure astrocytic tumours. Indeed, it is not surprising
that p53 protein accumulates in non-neoplastic tissue or in the
phenotypically normal tissue of cells from a cancer-prone family
(Barnes et al, 1992; Kurtkaya-Yapicier et al, 2002; Mawrin et al,
2003).
A number of studies, besides our own, indicate inverse
correlations among increased p53 expression and conventional
factors indicating a favourable clinical course in astrocytomas
(Chozick et al, 1994a; Iuzzolino et al, 1994; Korkolopoulou et al,
1998). Increased p53 protein was detected in a subset of low-grade
vs high-grade astrocytomas (Chozick et al, 1994a). Increased p53
expression occurred in the recurrent vs the initial tumour pairs
from the same patient, while tumours recurring within the same
histologic grade category, failed to reveal this increase (Chozick
et al, 1994a; Iuzzolino et al, 1994; Korkolopoulou et al, 1998;
Sarkar et al, 2002). We excluded tumours of oligodendroglial or
oligoastrocytic lineage from our analyses, because of the altered
natural history as compared to ‘pure’ astrocytomas, thus increas-
ing the likelihood of genetic mechanisms distinct from those of
pure astrocytomas (Burger et al, 1987; Shaw et al, 1992).
Interestingly, with respect to tumours of mixed or pure
oligodendrocytic lineage, alterations in p53 expression may also
portend a less favourable prognosis in the clinical setting (Soini
et al, 1994; Korkolopoulou et al, 1997; Miettinen et al, 2001).
Finally, pediatric tumours overexpressing p53 protein, revealed a
worse prognosis with increasing age (Pollack et al, 2002).
Our data indicate an interesting relationship between age and
p53 immunoreactivity in astrocytomas. In fact, while older age
correlated with an increase in p53 immunoreactivity on univariate
analyses, on multivariate analyses this effect conferred a rather
modest overall statistical benefit in progression-free survival.
Indeed, multivariate analyses indicated that the combination of
low p53 immunostaining scores and young age rendered an
approximate two-fold survival advantage. While this may seem
impressive with respect to the natural history of low-grade
tumours, the survival for high-grade astrocytomas and glioblasto-
ma multiforme is frequently in the range of months, rather than
years. The fact that multivariate analyses indicated an approximate
nine-fold advantage with respect to grade per se helps place these
statistical arguments into a clinical frame of reference (Table 3).
Increased p53 immunoreactivity resulted in decreased survival
with advancing age in a number of prior studies (Iuzzolino et al,
1994; Soini et al, 1994; Pollack et al, 2002). Of note, perhaps the
larger of these indicated, much like the trend in our own data, that
increased p53 immunoreactivity correlated with a worse prognosis
in older children (Pollack et al, 2002). However, this study, with
much larger numbers of young patient samples, as compared to
our own, found that the interesting correlation between increased
p53 expression and a worsened clinical course was age dependent.
Older age correlated with increases in p53 expression and this
correlation held up in multivariate analyses, even after controlling
for the strongest traditional prognosticator in the clinical setting,
histologic grade. The extent to which the inclusion of children less
than 18 years of age is unknown. A total of 13 cases less than 18
years old were included in the study. Only two cases less than 3
years of age were included. Interestingly, both cases expressed high
levels of p53 protein.
The existence of a subset of astrocytic tumours overexpressing
p53 protein, in the absence of detectable p53 mutations, invokes a
distinct role of apparently wild-type p53 expression in the natural
history of astrocytomas (Burton et al, 2002). This result is not
surprising given the spectrum of p53 function. An early study
emphasised the importance of normal human p53 overexpression
in the tumorigenic conversion of established fibroblasts (Tuck and
Crawford, 1989). Similar classic studies described p53 as an
antigen increased in SV40 virus-infected cells without p53
mutations (Bargonetti et al, 1991). Indeed, p53 expression is also
increased in cells treated with DNA-damaging agents (Okada et al,
2003). Normal cellular proteins that bind to p53 in a manner
similar to viral oncoproteins have been identified and found to be
potential oncogenes (Nees et al, 2001). Alternatively, increased p53
protein expression might be representative of progressive chromo-
somal damage, such as cells treated in vitro with ultraviolet or
gamma irradiation (Zhang et al, 1993; Agami and Bernards, 2000;
Denko et al, 2000).
Both the genetic and environmental factors modulate p53
function. Genetic links are suggested via the decreased expression
of p53 protein in a set of familial astrocytic tumours, as compared
to sporadic cases from the same institution (Malmer et al, 2002).
Three of our cases could be considered familial, as defined by the
presence of nonpilocytic astrocytomas in first-degree relatives. In
those six samples, revealing glioblastomas in both the patient and
the first-degree relative, the p53 immunostaining scores indicated
that between 25 and 50% of the cells stained positive. Genetics per
se cannot distinguish familial aetiologies without considering other
environmental factors including ethnicity and exposure to dietary
or environmental changes (Chen et al, 2001). Despite a strong
statistical correlation between our immunostaining results and
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sion, further study is necessary before p53 immunostaining is
routinely used in a prospective clinical setting. First of all, selection
bias cannot be completely eliminated in any retrospective study,
even with statistical analyses substantiating similarities to the
clinical population evaluated at the same institution during the
same time period. The use of the Bonferroni statistical correction
only partially compensates for the retrospective nature of the
analyses (Bowker and Lieberman, 1972). Although p53 expression
yielded additional information with respect to prognosis when the
two statistically strongest prognostic factors (i.e. grade and age)
were controlled for in multivariate analyses, we must emphasise
that grade per se remains the most important prognostic factor
with respect to actuarial survival on both univariate and multi-
variate analyses. Multivariate analyses indicate low p53 immunos-
taining scores and young age to render an approximate two-fold
survival advantage; however, low-grade histology per se yielded an
approximate nine-fold advantage (Table 3). Thus, the role of p53
expression in patient evaluation should be evaluated in conjunc-
tion with more traditional indices of glial tumour prognosis,
including patient age, and grade.
In summary, overexpression of total p53 protein, both mutant
and wild type, plays an important role in the natural history of
patients with astrocytic tumours. This observation suggests that
immunostaining of astrocytomas for overall p53 protein produc-
tion at diagnosis may be a valuable tool in the determination of
clinical course and be helpful in better tailoring modalities
of therapeutic intervention to the individual clinical case at
hand. Overexpression of p53 protein may not be associated
with mutations in coding exons of the p53 gene. Further
studies are needed in order to formulate a mechanistic explanation
for the enhanced accumulation of p53 protein in astrocytic
tumours. Elucidation of these mechanisms should further our
understanding of the clinical biology of astrocytic neoplasms, and
hopefully assist in improving therapeutic approaches for these
aggressive tumours.
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